|
Capromab
resources
|
|
|
|
|
|
DRUG INFO
Capromab
Drug Name:
Capromab
Indication: For diagnosis of prostate cancer and detection of intra-pelvic metastases
Pharmacology: Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors
Mechanism Of Action: Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Drug Category: Imaging Agents
Brand Names/Synonyms: ProstaScint; ProstaScint (Cytogen Corp)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Murine anti-7E11 antibody
Chemical Formula: Not Available
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00080
CAS Registry Number: 145464-28-4
|
|
|
|
|
|
Capromab News
(When available)
Cytogen to Raise $13.3 Million Through Sale of Common Stock and ... Dec 13, 2005
PR Newswire (press release), Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R) (capromab pendetide) kit for the preparation of ...
|
|
|
